{"id":707,"date":"2007-03-01T12:04:00","date_gmt":"2007-03-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/epileptische-kraempfe-nach-einnahme-von-vardenafil-und-sildenafil"},"modified":"2007-03-01T12:04:00","modified_gmt":"2007-03-01T11:04:00","slug":"epileptische-kraempfe-nach-einnahme-von-vardenafil-und-sildenafil","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/epileptische-kraempfe-nach-einnahme-von-vardenafil-und-sildenafil","title":{"rendered":"Epileptische Kr\u00e4mpfe nach Einnahme von Vardenafil und Sildenafil"},"content":{"rendered":"<p>Vardenafil (Levitra\u00ae) und Sildenafil (Viagra\u00ae) sind oral wirksame selektive Hemmer der Phosphodiesterase Typ 5, die f\u00fcr die Behandlung der erektilen Dysfunktion zugelassen sind. Beide Substanzen erh\u00f6hen in den Corpora cavernosa, aber auch in den Gef\u00e4\u00dfen einiger anderer Organe (z.B. Lunge), die Konzentration von Stickoxid (NO) und konsekutiv die intrazellul\u00e4re Konzentration von Guanosin-Monophosphat, wodurch die Erektion [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vardenafil (Levitra\u00ae) und Sildenafil (Viagra\u00ae) sind oral wirksame selektive Hemmer der Phosphodiesterase Typ 5, die f\u00fcr die Behandlung der erektilen Dysfunktion zugelassen sind. Beide Substanzen erh\u00f6hen in den Corpora cavernosa, aber auch in den Gef\u00e4\u00dfen einiger anderer Organe (z.B. Lunge), die Konzentration von Stickoxid (NO) und konsekutiv die intrazellul\u00e4re Konzentration von Guanosin-Monophosphat, wodurch die Erektion [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1816,1817,1818,806,1815],"class_list":["post-707","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-epileptische-anfaelle","tag-krampfanfall","tag-krampfanfaelle","tag-sildenafil","tag-vardenafil"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=707"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/707\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}